Childhood psychiatric disorders

Large Study Analyzes Two Different Classes of ADHD Drugs in Preschool-Age Children

Tuesday, May 4, 2021 - 10:30pm

The researchers found that both classes of drugs have benefits, with differing side effects, suggesting that decisions on which class of drugs to prescribe should be made based on individual patient factors.

Key Points: 
  • The researchers found that both classes of drugs have benefits, with differing side effects, suggesting that decisions on which class of drugs to prescribe should be made based on individual patient factors.
  • In contrast, children aged 5 to younger than 6 prescribed were likely to continue using the medication for longer if they were prescribed a stimulant.
  • "Future research should seek to learn more about the use of these classes of drugs in preschool-age children so that we can prescribe the most effective therapy for each patient.
  • In addition, its unique family-centered care and public service programs have brought the 595-bed hospital recognition as a leading advocate for children and adolescents.

OWP Pharmaceuticals Announces Patent Application for the First-Ever Oral Liquid Formulation of Atomoxetine Hydrochloride for the Treatment of Attention Deficit Hyperactivity Disorder

Thursday, April 22, 2021 - 1:00pm

b"NAPERVILLE, Ill., April 22, 2021 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations.

Key Points: 
  • b"NAPERVILLE, Ill., April 22, 2021 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations.
  • OWP announced today that it has submitted for U.S. patent protection, for the first-ever oral suspension of atomoxetine hydrochloride.
  • The medication is widely prescribed by healthcare providers in psychiatry for ADHD, and it is indicated for treatment in children 6 years and older and adults.
  • Some individuals with ADHD also display difficulty regulating emotions or problems with executive function.

Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD

Friday, April 2, 2021 - 9:58pm

Based on the efficacy demonstrated in the clinical program, we believe Qelbree offers a unique new alternative for the treatment of ADHD, said Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals.

Key Points: 
  • Based on the efficacy demonstrated in the clinical program, we believe Qelbree offers a unique new alternative for the treatment of ADHD, said Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals.
  • Qelbree provides prescribing physicians and patients living with ADHD a therapy that is not a controlled substance with proven efficacy and a tolerable safety profile.
  • This approval offers a novel once a day sprinkleable non-stimulant that can be a great option for children and adolescents with ADHD.
  • Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

PureTech Founded Entity Akili Announces the Results of EndeavorRx™ Clinical Study in Pediatric ADHD Published in Nature Digital Medicine

Friday, March 26, 2021 - 12:07pm

The results have been published in the international peer-reviewed journal, Nature Digital Medicine.

Key Points: 
  • The results have been published in the international peer-reviewed journal, Nature Digital Medicine.
  • The results have been published in the international peer-reviewed journal, Nature Digital Medicine.
  • Building on the results of the STARS-ADHD pivotal study of EndeavorRx published in The Lancet Digital Health in February 2020, the STARS Adjunct study evaluated the safety and efficacy of EndeavorRx when used alone and alongside stimulants.
  • EndeavorRx has been studied in more than 600 children with ADHD across five clinical trials, including a large, multicenter prospective randomized controlled study.

Results of Akili’s EndeavorRx™ Clinical Study Published in Nature Digital Medicine, Demonstrate Improvements in Pediatric ADHD Impairments and Symptoms in Daily Life

Friday, March 26, 2021 - 12:00pm

Statistically significant improvement was demonstrated in all predetermined endpoints of the study, which included parent and clinician ratings of childrens ADHD symptoms and related impairments in daily life.

Key Points: 
  • Statistically significant improvement was demonstrated in all predetermined endpoints of the study, which included parent and clinician ratings of childrens ADHD symptoms and related impairments in daily life.
  • Standard clinician ratings of impairments and symptoms were measured, as well as ratings by parents of their children in daily life.
  • A change in the ADHD Impairment Rating Scale (IRS), a parent-reported assessment scale of ADHD- specific impairments observed in their childs day-to-day life, was the primary outcome measure of the study.
  • EndeavorRx has been studied in more than 600 children with ADHD across five clinical trials, including a large, multicenter prospective randomized controlled study.

The Stroud Foundation and CHADD Partner Up to Improve Virtual Learning for Children with ADHD

Thursday, March 11, 2021 - 4:00pm

Dr. Chronis-Tuscano and her team were selected through a competitive application process and thorough review by a committee of experts in ADHD representing both the Stroud Foundation and CHADD.

Key Points: 
  • Dr. Chronis-Tuscano and her team were selected through a competitive application process and thorough review by a committee of experts in ADHD representing both the Stroud Foundation and CHADD.
  • We're delighted to partner with CHADD and the experts at the University of Maryland to deliver high-yield, low-cost, real-world support for families of children with ADHD."
  • The Stroud Foundation is a tax-exempt public charity established in 2008 to honor the memory of pediatrician Dr. Frank Stroud.
  • The foundation is dedicated to improving the lives of children with learning differences and their families in the DC area, with a particular focus on children with attention-deficit/hyperactivity disorder (ADHD).

CHADD Honors Exceptional Contributions to the ADHD Community with Annual Awards

Monday, March 8, 2021 - 4:00pm

The 2020 Affiliate of the Year Award has been presented to CHADD Philadelphia in recognition of outstanding service to the community.

Key Points: 
  • The 2020 Affiliate of the Year Award has been presented to CHADD Philadelphia in recognition of outstanding service to the community.
  • Hall of Fame honorees are recognized for their leadership, innovation, and dedication to serving the ADHD community; their exceptional contributions to the field; and their steadfast commitment to CHADD.
  • The Lifetime Achievement Award is CHADD's highest honor, created to recognize sustained, fundamental, and outstanding contributions to the field of ADHD.
  • "We celebrate the exceptional contributions all of our 2020 award recipients have made to the ADHD community," said Robert Cattoi, Chief Executive Officer, CHADD.

KemPharm to Present at the 33rd Annual Roth Conference

Thursday, March 4, 2021 - 9:41pm

The complete label for AZSTARYS, including prescribing information and important safety information, may be found at https://kempharm.com/wp-content/uploads/2021/03/AZSTARYS-Master-Label-Fi... .

Key Points: 
  • The complete label for AZSTARYS, including prescribing information and important safety information, may be found at https://kempharm.com/wp-content/uploads/2021/03/AZSTARYS-Master-Label-Fi... .
  • KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT (Ligand Activated Therapy) technology.
  • KemPharm is also advancing several clinical development candidates, including KP484 for the treatment of ADHD and KP879 for the treatment of Stimulant Use Disorder (SUD).
  • In addition, KemPharm has received FDA approval for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.

NLS Pharmaceutics to Participate in Upcoming Investor Conferences

Thursday, February 25, 2021 - 2:00pm

Maxim 2021 Emerging Growth Virtual Conference hosted by M-Vest on March 17, 2021.

Key Points: 
  • Maxim 2021 Emerging Growth Virtual Conference hosted by M-Vest on March 17, 2021.
  • The Company's presentation for this conference will be available on M-Vest following the conference.
  • NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system disorders.
  • NLS completed a phase 2 study in the U.S. evaluating mazindol CR in adult subjects with ADHD.

Supernus Receives FDA Notice Assigning Early April 2021 PDUFA Date for SPN-812 NDA

Monday, February 22, 2021 - 1:00pm

Supernus will continue to work closely with the FDA as it completes its review of the SPN-812 NDA.

Key Points: 
  • Supernus will continue to work closely with the FDA as it completes its review of the SPN-812 NDA.
  • If approved by the FDA, the Company is preparing for the commercial launch of SPN-812 for the treatment of ADHD in pediatric patients in the second quarter of 2021.
  • In December 2020, Supernus announced positive results from a Phase III study for SPN-812 in adults with ADHD.
  • The Company plans to submit a supplemental NDA (sNDA) to the FDA for SPN-812 for the treatment of ADHD in adult patients in the second half of 2021, assuming approval for pediatric patients.